NCT00401115View on ClinicalTrials.gov

Safety and Tolerability of MS-R001 in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

June 30, 2008

Study Completion Date

June 30, 2008

Conditions
Diabetic Macular EdemaDiabetic Retinopathy
Interventions
DRUG

MS-R001 (rapamycin)

Subconjunctival injection in various dosages

DRUG

MS-R001 (rapamycin)

Intraocular injection in various dosages

Trial Locations (2)

76012

Texas Retina Associates, Arlington

85014

Retina Consultants of Arizona, Phoenix

All Listed Sponsors
collaborator

MacuSight, Inc.

INDUSTRY

lead

Santen Inc.

INDUSTRY

NCT00401115 - Safety and Tolerability of MS-R001 in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy | Biotech Hunter | Biotech Hunter